MedicaidPrior AuthMedium impact
MAB2023110805
Pennsylvania Medicaid (DHS)·PA · Dermatology, Allergy & Immunology, Family Medicine +1 more·Provider Bulletin
Effective date
Jan 8, 2024
We identified it
Jun 20, 2026
Summary
Pennsylvania Medicaid is implementing new prior authorization requirements for atopic dermatitis immunomodulator medications, including topical JAK inhibitors, PDE4 inhibitors, and targeted systemic treatments. The policy establishes step therapy requirements and prohibits concurrent use of multiple targeted systemic agents.
Action Required
By January 8, 2024: Billing and clinical teams must update prior authorization workflows for Pennsylvania Medicaid patients prescribed atopic dermatitis immunomodulators. Ensure prescribers document required step therapy trials (4-week topical corticosteroids, 8-week topical calcineurin inhibitors) before prescribing JAK inhibitors or PDE4 inhibitors. Verify specialist consultation documentation for targeted systemic agents. Update EMR templates to capture contraindications and therapeutic failures. Claims will be denied without proper prior authorization.